深圳市易瑞生物技术股份有限公司 2022 年第三季度报告 证券代码：300942 证券简称：易瑞生物 公告编号：2022-094 深圳市易瑞生物技术股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 上年同期增减 | | 营业收入（元） | 97,425,576.62 | -3.14% | 572,094,603.75 | 32.71% ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥474,669,027.13, representing a 43.63% increase compared to ¥330,490,442.36 in the same period last year[21]. - The net profit attributable to shareholders decreased by 7.28% to ¥151,413,759.86 from ¥163,308,712.30 year-on-year[21]. - The net cash flow from operating activities significantly dropped by 91.18% to ¥16,473,397.52, down from ¥186,855,394.45 in the previous year[21]. - The total assets increased by 10.52% to ¥1,273,731,841.06 compared to ¥1,152,520,292.55 at the end of the previous year[21]. - The net assets attributable to shareholders rose by 8.30% to ¥1,023,183,519.34 from ¥944,762,745.98 at the end of the previous year[21]. - The basic earnings per share decreased by 9.52% to ¥0.38 from ¥0.42 in the same period last year[21]. - The weighted average return on net assets fell to 14.88% from 21.93% year-on-year, a decrease of 7.05%[21]. - The company's revenue for the reporting period reached ¥474,669,027.13, representing a 43.63% increase compared to ¥330,490,442.36 in the previous year, primarily driven by growth in the in vitro diagnostic business[91]. - The cost of sales increased by 125.03% to ¥168,126,597.67, up from ¥74,712,530.84, due to rising key raw material and labor costs associated with increased revenue[91]. Research and Development - The company invested 40.73 million yuan in R&D, a year-on-year increase of 34.94%, focusing on core antigen-antibody research and product certification[37]. - The company has maintained high R&D investment, focusing on antigen-antibody research and development, resulting in a diverse product output[78]. - The company has a strong capability for new product development, leveraging its proprietary antigen and antibody preparation technology to create diverse product offerings[84]. - The company has developed a rapid solid-phase extraction (SPE) technology that simplifies the sample preparation process from five steps to two, enhancing detection efficiency and accuracy[86]. - The company emphasizes the importance of R&D innovation and has established collaborations with research institutions to enhance its technological capabilities[130]. Market and Product Development - The company focuses on rapid detection technology applied in food safety and in vitro diagnostics, with no significant changes in its main business during the reporting period[30]. - The main products include rapid detection reagents and instruments for food safety, as well as various POCT products for clinical diagnostics[30]. - The company has developed a series of products for drug detection, thyroid function testing, cardiovascular disease detection, and more, utilizing multiple R&D platforms[31]. - The company is positioned to capture market share through its core technology advantages in antigen-antibody raw material development[56]. - The company achieved significant growth in overseas sales, enhancing product penetration in international markets through effective marketing and partnerships with international dairy groups and agricultural departments[58]. - The POCT (Point of Care Testing) business is in a high-growth phase, with the market expected to expand rapidly due to increasing demand and stable technology[59]. - The global POCT market size was approximately $29.5 billion in 2020, projected to reach $50.6 billion by 2025, with a compound annual growth rate (CAGR) of about 11.4%[69]. - The domestic food safety rapid testing market is expected to grow from approximately 19.68 billion yuan in 2016 to 91.75 billion yuan by 2022, with a CAGR of 25.24%[67]. Corporate Governance and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's management[3]. - All directors attended the board meeting to review the report, ensuring comprehensive oversight[4]. - The report includes a section on corporate governance and social responsibility, highlighting the company's commitment to ethical practices[5]. - The company has established a governance structure that includes a shareholders' meeting, board of directors, independent directors, and a supervisory board to protect shareholder rights[149]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[147]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[147]. - The company has implemented measures to comply with environmental regulations and has not faced any violations during the reporting period[147]. Financial Management and Fundraising - The total fundraising amount reached RMB 175.35 million after deducting various issuance costs[115]. - Cumulative investment of RMB 24.51 million from the fundraising as of June 30, 2022[115]. - The company temporarily supplemented working capital with RMB 65 million from the fundraising[115]. - The balance of the special account for fundraising was RMB 1.52 million as of June 30, 2022[115]. - The company has signed a tripartite supervision agreement with banks and sponsors for the management of fundraising[115]. - The company has reported a total of RMB 373.4 million in entrusted financial management, with RMB 284 million from self-owned funds and RMB 88.4 million from raised funds[122]. Risks and Challenges - The company faces risks related to the dependency on imported raw materials, particularly nitrocellulose membranes, which are crucial for its products[132]. - The company acknowledges the uncertainty and unsustainability of revenue growth driven by COVID-19 testing products, which may be affected by global pandemic conditions[131]. - The company has experienced rapid business expansion, particularly in in vitro diagnostics and animal diagnostics, which has increased management risks due to the need for enhanced operational capabilities[133]. - The company plans to strengthen its corporate culture and management systems to mitigate risks associated with rapid growth[133]. Shareholder Information - The company did not distribute cash dividends or issue bonus shares for the half-year period[141]. - The company approved a stock incentive plan in 2021, granting 6.55 million restricted shares at a price of 16.22 CNY per share to 55 eligible participants[143]. - The company held three temporary shareholder meetings in 2022, with participation rates of 71.89%, 74.93%, and 74.95% respectively[138]. - The total number of common shareholders at the end of the reporting period was 18,037[187]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[192]. Strategic Initiatives - The company is actively expanding its international market presence and enhancing its operational management to mitigate risks from potential policy changes[128]. - The company aims to maintain global health as its mission, focusing on food and drug safety, in vitro diagnostics, and public safety[148]. - The company has established a wholly-owned subsidiary, enhancing its operational capabilities and market presence[175]. - The company has engaged in partnerships with professional investment institutions to explore investment opportunities, indicating a strategic focus on growth[176].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 300 million RMB in 2021, representing a growth of 25% year-over-year [16]. - The company's operating revenue for 2021 was CNY 597,539,623.17, representing a 131.20% increase compared to CNY 258,455,671.51 in 2020 [20]. - The net profit attributable to shareholders for 2021 was CNY 236,507,393.22, a significant increase of 261.38% from CNY 65,445,058.17 in 2020 [20]. - The net profit after deducting non-recurring gains and losses was CNY 213,698,482.19, up 275.71% from CNY 56,877,824.49 in 2020 [20]. - The net cash flow from operating activities reached CNY 255,424,985.52, marking a 300.39% increase from CNY 63,793,860.76 in 2020 [20]. - The company's basic earnings per share for 2021 was CNY 0.6, reflecting a 233.33% increase from CNY 0.18 in 2020 [20]. - The weighted average return on equity for 2021 was 29.41%, up from 12.32% in 2020, indicating improved profitability [20]. - The company achieved a revenue of 597.54 million yuan, representing a year-on-year growth of 131.20% [69]. - The net profit attributable to shareholders reached 236.51 million yuan, an increase of 261.38% compared to the previous year [69]. - The revenue from food safety rapid detection business was 182.53 million yuan, showing a slight growth of 1.38% year-on-year [70]. - The revenue from in vitro diagnostic rapid testing (POCT) business surged to 415.01 million yuan, a significant increase of 429.27% year-on-year, driven by sales of COVID-19 antigen testing solutions [72]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 2.49 RMB per 10 shares to all shareholders, based on a total of 400,860,000 shares [5]. Market Expansion and Strategy - The company provided a positive outlook for 2022, projecting a revenue growth of 30% driven by new product launches and market expansion efforts [16]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share within the next two years [16]. - A strategic acquisition of a local biotech firm was announced, expected to enhance the company's product portfolio and increase market competitiveness [16]. - The company is actively pursuing partnerships with international distributors to broaden its global reach and improve sales channels [16]. - The company aims to deepen its focus on food safety rapid testing and provide customized comprehensive solutions to achieve international market growth [141]. - The company plans to expand its POCT business and develop a product line focused on infectious disease detection, targeting key overseas markets [142]. Research and Development - Investment in R&D increased by 15%, focusing on the development of new diagnostic technologies and enhancing existing product lines [16]. - The company invested 72.43 million yuan in R&D, marking a 79.01% increase from the previous year [74]. - The company launched over 110 new products in the food safety sector, including a multi-residue rapid test strip for detecting 16 pesticide residues [77]. - The company has developed over 120 self-produced antigens and 140 self-produced antibodies, achieving a high level of self-sufficiency in key raw materials for rapid testing products [60]. - The company has been recognized for its contributions to scientific advancements, receiving multiple awards for its R&D efforts [183]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and strategies, as outlined in the management discussion section [5]. - The report includes a detailed analysis of potential risk factors that the company may face in the future [5]. - The company faces risks related to policy changes and industry regulations, which could impact its operational performance, and it is committed to adapting to these changes [147]. - The company recognizes the uncertainty and unsustainability of revenue growth driven by the COVID-19 pandemic and is preparing for potential market fluctuations [150]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights [157]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a diverse range of expertise [159]. - The company maintains independence from its controlling shareholders, with no significant related party transactions or competition [165]. - The company has implemented a robust information disclosure system to ensure transparency and timely communication with investors [162]. - The company is committed to enhancing its internal control and governance practices as indicated in its self-evaluation report [192]. Sustainability and Social Responsibility - The management emphasized a commitment to sustainability, aiming to reduce operational costs by 10% through improved efficiency measures [16]. - The company is committed to balancing the interests of stakeholders, including shareholders, employees, and the community, to promote sustainable development [163]. Employee and Management Structure - The total number of employees at the end of the reporting period is 650, with 382 in the parent company and 268 in major subsidiaries [200]. - The company has a diverse management team with members having extensive experience in various industries, including finance and biotechnology [184]. - The educational background of employees includes 6 with a doctorate, 26 with a master's degree, 240 with a bachelor's degree, and 378 with an associate degree or below [200]. Product Development and Innovation - The company focuses on rapid testing technology applied in food safety and in vitro diagnostics, with major business segments being food safety rapid testing and POCT (Point of Care Testing) [40]. - The company has established a comprehensive quality management system, holding multiple certifications including ISO13485:2016 and ISO9001:2015 [48]. - The company has developed new products for animal testing, including detection methods for various diseases in livestock [78]. - The company has successfully developed diagnostic products for animal diseases and established production lines, with plans to accelerate the industrialization of these products [143].

Financial Performance - The company's revenue for Q1 2022 reached ¥294,001,215.63, representing a 100.11% increase compared to ¥146,917,926.77 in the same period last year[4] - Net profit attributable to shareholders was ¥114,128,972.49, a 30.27% increase from ¥87,610,355.16 year-over-year[4] - Basic and diluted earnings per share increased by 21.74% to ¥0.28 from ¥0.23[4] - The net profit after deducting non-recurring gains and losses was RMB 108 million, up 36.32% year-on-year[15] - The company’s total operating revenue reached CNY 294,001,215.63 for the current period, a significant increase from CNY 146,917,926.77 in the previous period, representing a growth of approximately 100%[21] - The net profit for Q1 2022 was CNY 114,098,297.86, an increase of 30.3% compared to CNY 87,599,429.10 in Q1 2021[22] - The total comprehensive income for Q1 2022 was CNY 114,017,886.19, compared to CNY 86,965,485.64 in the same period last year[22] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥51,177,229.38, a decline of 152.13% compared to ¥98,176,735.85 in the previous year[4] - The company's cash and cash equivalents decreased to CNY 306,951,385.94 from CNY 342,211,180.47 at the beginning of the year, a decline of approximately 10.2%[17] - The cash flow from operating activities showed a net outflow of CNY -51,177,229.38, compared to a net inflow of CNY 98,176,735.85 in the same period last year[24] - The company reported cash and cash equivalents at the end of Q1 2022 amounting to CNY 303,982,289.69, down from CNY 464,332,177.81 at the end of Q1 2021[26] - The company generated CNY 437,566,466.36 in cash inflow from investment activities, significantly higher than CNY 206,207,905.11 in the previous year[24] - The net cash flow from investment activities was CNY 15,956,035.85, recovering from a net outflow of CNY -190,871,815.39 in Q1 2021[26] Assets and Liabilities - Total assets grew by 16.17% to ¥1,338,832,695.50 from ¥1,152,520,292.55 at the end of the previous year[4] - The total liabilities increased to CNY 264,902,209.87 from CNY 205,940,193.12, representing a rise of approximately 28.6%[19] - The company's retained earnings rose to CNY 466,114,874.37 from CNY 351,985,901.88, an increase of about 32.4%[20] - Accounts receivable increased significantly to CNY 201,003,768.99 from CNY 97,051,672.70, reflecting a growth of about 106.5%[17] - The inventory level rose to CNY 119,298,357.46 from CNY 93,859,305.88, marking an increase of approximately 27.1%[18] Research and Development - Research and development expenses increased by 45.98% to ¥15,605,979.98 as the company focused on industry trends[8] - The company continues to increase R&D investment to enhance product development and intellectual property protection[15] - The company added 7 new authorized patents during the reporting period, including 3 domestic invention patents and 2 overseas patents[15] Business Expansion and Partnerships - The company expanded its POCT business sales channels through a partnership with Hong Kong Xiangda Biological[15] - The company established a wholly-owned subsidiary, Aido Biology, to enhance product innovation and accelerate the acquisition of new veterinary drug certifications[16] - The company has partnered with professional investment institutions to establish Zhengrui Investment, aimed at enhancing the overall competitiveness and expanding the industrial chain[16] Market and Regulatory Environment - The demand for COVID-19 testing products remains strong due to the ongoing impact of the Omicron variant[15] - The company is committed to monitoring the pandemic situation to contribute to domestic and international epidemic prevention efforts[15] - The company obtained domestic medical device registration for its COVID-19 antigen test kit in March 2022[15] Operating Costs - The gross profit margin was impacted by a 311.55% increase in operating costs, which reached ¥96,408,256.89[8] - The total operating costs for the current period were CNY 155,220,845.49, compared to CNY 57,064,106.14 in the previous period, indicating an increase of about 172%[21] Shareholder Information - The company’s major shareholder, Shenzhen Yirui Holdings, holds 37.67% of the shares, with 151 million shares pledged[10]

证券代码：300942 证券简称：易瑞生物 公告编号：2021-097 深圳市易瑞生物技术股份有限公司 关于参加 2021 深圳辖区"沟通传递价值，交流创造良好生态" 上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，深圳市易瑞生物技术股份有限公司 （以下简称"公司"）将参加由深圳上市公司协会、深圳市全景网络有限公司共 同举办的"沟通传递价值，交流创造良好生态"——2021 深圳辖区上市公司投 资者网上集体接待日活动，现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net/） 或关注微信公众号：全景财经，参与公司本次投资者集体接待日活动，活动时间 为 2021 年 11 月 30 日 14:00 至 17:00。 届时公司的董事会秘书张煜堃先生和财务总监王广生先生将通过网络文字 交流形式与投资者进行沟通。 欢迎广大投资者积极参与。 特此公告。 深圳市易瑞生物技术 ...

Financial Performance - The company's revenue for Q3 2021 reached ¥100,582,552, representing an increase of 83.18% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥32,352,658.58, a significant increase of 155.13% year-over-year[3]. - The net profit excluding non-recurring gains and losses was ¥29,166,302.65, up 206.59% from the previous year[3]. - The basic earnings per share (EPS) was ¥0.0807, reflecting a growth of 129.26% compared to the same quarter last year[3]. - The company achieved operating revenue of CNY 431.07 million for the first three quarters of 2021, representing a year-on-year growth of 131.15%[14]. - The net profit attributable to shareholders reached CNY 195.66 million, a year-on-year increase of 277.03%[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 178.01 million, up 295.30% year-on-year[14]. - Total operating revenue for Q3 2021 reached ¥431,072,994.36, a significant increase of 131.3% compared to ¥186,494,430.62 in Q3 2020[21]. - Operating profit for Q3 2021 was ¥224,027,270.13, up from ¥58,981,752.58 in the same period last year, reflecting a growth of 278.5%[22]. - Net profit for Q3 2021 amounted to ¥195,631,959.45, compared to ¥51,909,188.28 in Q3 2020, representing an increase of 276.5%[22]. - The total comprehensive income for the period was CNY 194,894,966.29, compared to CNY 51,816,554.12 in Q3 2020, marking an increase of about 275.5%[23]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,107,073,439.24, an increase of 69.57% from the end of the previous year[3]. - Total current assets as of September 30, 2021, were ¥896,503,395.57, up from ¥526,129,020.88 at the end of 2020, indicating a growth of 70.3%[18]. - Total assets reached ¥1,107,073,439.24 as of September 30, 2021, compared to ¥652,886,483.47 at the end of 2020, marking an increase of 69.5%[19]. - Total liabilities increased to ¥205,909,931.81 in Q3 2021 from ¥103,903,179.01 in Q3 2020, reflecting a growth of 97.8%[19]. - Total liabilities reached CNY 103,903,179.01, with non-current liabilities at CNY 25,783,875.37[30]. - Current liabilities totaled CNY 78,119,303.64, with accounts payable at CNY 14,644,174.02[29]. - The total liabilities and owner's equity combined amounted to CNY 652,886,483.47[30]. Cash Flow - Cash flow from operating activities for the year-to-date reached ¥200,984,268.99, showing a remarkable increase of 417.19%[3]. - Net cash flow from operating activities was CNY 200,984,268.99, compared to CNY 38,861,074.17 in Q3 2020, indicating a growth of over 416%[26]. - The company reported a net cash outflow from investing activities of CNY -488,920,887.28, compared to CNY -354,702,861.41 in the same period last year[26]. - Cash inflow from financing activities was CNY 195,740,100.00, significantly higher than CNY 22,000,000.00 in Q3 2020[26]. - The company paid CNY 18,038,700.00 in dividends and interest, down from CNY 45,354,479.33 in the previous year[26]. Research and Development - Research and development expenses for Q3 2021 were ¥45,738,147.09, compared to ¥30,478,620.64 in Q3 2020, an increase of 50.0%[22]. - The company added 6 new authorized patents during the reporting period, including 1 invention patent[15]. Regulatory and Compliance - The company participated in the formulation of the national standard for "Immunochromatographic Test Strip Detection General Principles," which was approved and published[15]. - The company obtained a Class III medical device registration certificate for the HIV antibody test kit (colloidal gold method) in domestic registration[15]. - The company secured over 40 new EU CE certifications for international registration during the reporting period[15]. - The company has implemented new leasing standards affecting the financial statements, indicating a proactive approach to compliance and financial management[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 15,707[10]. - The company launched a restricted stock incentive plan draft in 2021 to enhance its incentive mechanism and support high-quality development[15]. - The company was included in the third batch of "specialized and innovative" small giant enterprises by the Ministry of Industry and Information Technology, indicating recognition of its advanced technology and business expansion[14]. Other Financial Metrics - The weighted average return on equity (ROE) improved to 3.65%, an increase of 1.25% year-over-year[3]. - The company reported a decrease in other comprehensive income, with a net amount of -¥766,404.59 in Q3 2021 compared to -¥78,983.41 in Q3 2020[22]. - The company recognized a right-of-use asset increase of CNY 44,711,437.99 due to the new leasing standard[30]. - The report for the third quarter was not audited[31].

Financial Performance - The company's revenue for the reporting period reached ¥330,490,442.36, representing a 151.16% increase compared to ¥131,586,778.83 in the same period last year[22]. - Net profit attributable to shareholders was ¥163,308,712.30, a significant increase of 316.45% from ¥39,214,478.51 in the previous year[22]. - The net cash flow from operating activities was ¥186,855,394.45, showing a remarkable increase of 5,216.83% compared to a negative cash flow of ¥3,651,781.73 in the same period last year[22]. - Basic earnings per share increased to ¥0.42, up 281.82% from ¥0.11 in the previous year[23]. - Total assets at the end of the reporting period were ¥1,088,282,961.78, a 66.69% increase from ¥652,886,483.47 at the end of the previous year[23]. - The net assets attributable to shareholders increased to ¥869,133,460.58, reflecting a growth of 58.30% from ¥549,053,562.88 at the end of the previous year[23]. - Operating profit surged to ¥182,792,891.81, reflecting a 301.21% increase from ¥45,560,011.97 in the prior year, attributed to the overall revenue growth[67]. - The company's net profit for the first half of 2021 was CNY 166,351,744.17, a significant increase from CNY 41,187,012.13 in the same period of 2020, representing a growth of 303.5%[188]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the CEO and accounting head[3]. - All board members attended the meeting to review the report, ensuring comprehensive oversight[4]. - The report includes a section on corporate governance, highlighting the company's commitment to transparency and accountability[7]. - The company completed its registration changes and obtained a new business license on April 12, 2021, following a series of corporate governance updates[21]. Strategic Developments - The company has outlined its future plans and strategic developments, although these do not constitute a commitment to investors[4]. - The company is advancing the registration of over 40 in vitro diagnostic products, with 16 new CE certifications obtained[36]. - The company is implementing a localized strategy for overseas sales to better serve local customers[36]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth momentum[182]. Research and Development - The company invested 30.18 million yuan in R&D, representing a 60.13% increase year-on-year[34]. - The company launched 76 new products, including a multi-residue rapid test strip for pesticide residues[34]. - The company has developed new technologies for animal testing, including multi-detection products for various diseases, which are expected to become new profit growth points[38]. - Research and development investment rose by 60.13% to ¥30,179,783.86, up from ¥18,847,467.83, highlighting the company's commitment to innovation[67]. Market Expansion - The company expanded its international market presence, covering over 60 countries and regions[36]. - The company established a marketing network covering over 60 countries, including Russia, France, and Italy, enhancing its market expansion capabilities[64]. - The company has developed customized products to meet diverse customer needs, enhancing sales through technological advantages[48]. Financial Management - The company raised a net amount of 175.35 million CNY from its IPO on the Shenzhen Stock Exchange in February 2021, marking a new phase of "industry + capital" development[39]. - The company has cash management of RMB 100 million from idle raised funds, with the remainder stored in a dedicated account[90]. - The company reported a total cash outflow from investing activities of ¥698,029,744.80, up from ¥514,350,490.66 in the previous period, indicating increased capital expenditures[195]. Compliance and Risk Management - The company is actively monitoring industry policies to mitigate risks associated with regulatory changes in the food safety testing sector[100]. - The company emphasizes the importance of compliance with local regulations for its products in international markets[101]. - The company faces risks related to reliance on imported raw materials, particularly nitrocellulose membranes, which are essential for its immunochromatographic testing products[105]. Shareholder Information - The company successfully completed its initial public offering, issuing 40.86 million shares, with trading commencing on February 9, 2021[144]. - The total number of ordinary shareholders at the end of the reporting period is 25,066[160]. - Shenzhen Yirui Holdings Co., Ltd. holds 37.67% of shares, totaling 151,001,310 shares, with no changes during the reporting period[160]. Environmental and Social Responsibility - The company does not belong to the key pollutant discharge units and has not faced any environmental penalties during the reporting period[117]. - There were no significant social responsibility initiatives reported during the period, such as poverty alleviation or rural revitalization efforts[118].

Financial Performance - The company's revenue for Q1 2021 was ¥146,917,926.77, representing a 103.46% increase compared to ¥72,209,692.72 in the same period last year[7] - Net profit attributable to shareholders for Q1 2021 was ¥87,610,355.16, a 150.10% increase from ¥35,030,572.53 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥79,440,063.33, up 133.33% from ¥34,045,540.77 in the previous year[7] - The basic earnings per share for Q1 2021 was ¥0.23, reflecting a 155.56% increase from ¥0.09 in the same quarter last year[7] - The company reported a net profit of CNY 89,853,820.63 for the quarter, reflecting strong operational performance[47] - The net profit for Q1 2021 reached CNY 87,599,429.10, up from CNY 35,021,960.21 in the same period last year, representing a growth of approximately 150%[48] - The total comprehensive income for Q1 2021 was CNY 86,965,485.64, compared to CNY 35,300,634.11 in the prior year, showing a growth of about 146%[49] Assets and Liabilities - The total assets at the end of the reporting period were ¥998,848,324.21, a 52.99% increase from ¥652,886,483.47 at the end of the previous year[7] - The total assets of the company reached CNY 998.85 million, up from CNY 652.89 million at the end of 2020, indicating a growth of 52.8%[39] - Total liabilities rose to CNY 176,648,028.56, compared to CNY 103,348,477.74 in the previous period[44] - Total current liabilities stand at CNY 77,564,602.37, showing a stable short-term financial position[67] Cash Flow - The net cash flow from operating activities was ¥98,176,735.85, a significant recovery from a negative cash flow of -¥20,689,163.91 in the same period last year[7] - Cash flow from operating activities was CNY 168,141,233.13, significantly higher than CNY 68,922,745.94 in the same period last year, demonstrating improved cash generation[55] - The net cash flow from financing activities was ¥182,706,115.09, a substantial increase from ¥21,997,320.65 in the previous year, highlighting successful fundraising efforts[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,501[10] - The largest shareholder, Shenzhen Yirui Holdings Co., Ltd., held 37.67% of the shares, amounting to 151,001,310 shares[10] Research and Development - R&D investment totaled 10.69 million yuan, up 27.73% from the same period last year, accounting for 7.28% of total revenue[19] - Research and development expenses for Q1 2021 amounted to CNY 10,690,252.58, compared to CNY 8,247,570.76 in the previous year, indicating an increase in investment in innovation[51] Government Subsidies and Other Income - The company received government subsidies amounting to ¥9,595,211.92 during the reporting period[8] - The company achieved a 210.57% increase in other income, totaling ¥3,595,211.92, primarily due to increased government subsidies[18] Inventory and Accounts Receivable - The company reported a significant increase in accounts receivable, rising by 745.11% to ¥2,693,583.00 due to an increase in bank acceptance bills received[17] - Inventory increased by 42.94% to ¥88,038,529.64, reflecting the company's growth in revenue and stock preparation[17] Market Presence and Future Plans - The company plans to expand its production capacity, leading to an increase in non-current assets by 98.97% to ¥13,550,104.77[17] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[47] Compliance and Governance - The company has undergone a board and supervisory committee restructuring, with new members elected in March 2021[26] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[33]

Financial Performance - The company's operating revenue for 2020 was CNY 258,455,671.51, an increase of 8.06% compared to CNY 239,178,001.68 in 2019[19]. - The net profit attributable to shareholders for 2020 was CNY 65,445,058.17, a decrease of 29.10% from CNY 92,308,448.82 in 2019[19]. - The net profit after deducting non-recurring gains and losses was CNY 56,877,824.49, down 24.89% from CNY 75,722,397.27 in 2019[19]. - The basic earnings per share for 2020 was CNY 0.18, a decline of 30.77% compared to CNY 0.26 in 2019[19]. - The total assets at the end of 2020 were CNY 652,886,483.47, representing a 5.36% increase from CNY 619,665,211.31 at the end of 2019[19]. - The net assets attributable to shareholders at the end of 2020 were CNY 549,053,562.88, an increase of 3.91% from CNY 528,394,104.82 at the end of 2019[19]. - The cash flow from operating activities for 2020 was CNY 63,793,860.76, a decrease of 5.13% from CNY 67,243,603.60 in 2019[19]. - The weighted average return on equity for 2020 was 12.32%, down from 19.62% in 2019, a decrease of 7.30%[19]. - The company reported a decrease in operating profit to 75.11 million yuan, down 28.63% year-on-year[57]. - The company achieved total operating revenue of 258.46 million yuan in 2020, an increase of 8.06% compared to the previous year[57]. Dividend Distribution - The company plans to distribute a cash dividend of 0.45 RMB per 10 shares based on a total share capital of 400,860,000 shares as of March 31, 2021[5]. - The cash dividend represents 100% of the total profit distribution amount for the year[114]. - The cash dividend payout ratio for 2020 is 27.56% of the net profit attributable to the parent company[118]. - The company did not issue any bonus shares or increase capital from reserves during the reporting period[116]. - The independent directors confirmed their agreement with the dividend distribution plan[115]. Business Strategy and Market Position - The company is focused on expanding its market presence and developing new products and technologies to enhance its competitive edge[7]. - The report covers the operational performance and future outlook, detailing the company's strategic direction and potential challenges[5]. - The company has outlined its business overview and key financial indicators in the annual report, providing insights into its market position[7]. - The company aims to deepen its focus on food safety rapid testing while expanding into POCT and animal disease detection, creating an integrated detection ecosystem[102]. - The company plans to develop high-end technology products such as portable mass spectrometers and biosensors, maintaining its R&D capabilities and technological advantages[103]. Research and Development - The company has invested significantly in R&D, focusing on technology innovation and product development to maintain its competitive edge[51]. - The company invested 40.46 million yuan in R&D during the reporting period, representing a year-on-year increase of 20.12% and accounting for 15.66% of total revenue, ensuring continuous output of R&D results[60]. - The company has developed over 400 high-precision rapid testing reagents, focusing on detecting pesticide residues, veterinary drug residues, and pathogenic microorganisms[30]. - The company has established a robust R&D model combining independent research and technical cooperation, focusing on market-driven needs and cutting-edge technology[32]. - The company has developed five major technology platforms in the in vitro diagnostic business, completing over 70 product developments across three major product series: drug detection, infectious disease detection, and chronic disease management[63]. Operational Challenges and Risks - The company acknowledges the uncertainty and potential unsustainability of revenue growth from COVID-19 related products, which depends on various external factors[109]. - The company faces risks related to policy changes that could impact its operations and the food safety testing industry, necessitating timely adjustments to its business strategies[108]. - The rapid expansion of the company's operations into new business areas may lead to management challenges if the management team and systems do not keep pace with growth[110]. - The company is reliant on imported raw materials, particularly nitrocellulose membranes, which poses a risk to production costs and supply stability[109]. Governance and Compliance - The company has outlined its governance structure and shareholder information, emphasizing transparency and compliance with regulatory requirements[7]. - The report indicates that all board members attended the meeting to review the annual report, ensuring collective accountability[4]. - The company emphasizes the protection of shareholder and creditor rights, adhering to relevant laws and regulations[142]. - The independent directors attended all 9 board meetings and 6 shareholder meetings during the reporting period[196]. - The company maintains a structured approach to governance through its various committees[200]. Market Trends and Growth Opportunities - The global food safety testing market is projected to grow from $12.01 billion in 2016 to $18.54 billion by 2022, with a compound annual growth rate (CAGR) of approximately 7.6%[39]. - The global food rapid testing market is expected to increase from $10.14 billion in 2016 to $15.71 billion by 2022, accounting for about 85% of the total food safety testing market[40]. - The domestic food safety rapid testing market size was approximately RMB 2.977 billion in 2017, with a projected compound annual growth rate (CAGR) of 25.24% from 2017 to 2022, reaching RMB 9.175 billion by 2022[42]. - The company is diversifying into in vitro diagnostics and animal disease businesses, which are expected to provide new growth points for performance[39]. - The company has successfully developed testing products for African swine fever, foot-and-mouth disease, and other animal diseases, with plans to accelerate the layout of its animal disease testing business to capture new profit growth points[106]. Employee and Management Structure - The company employed a total of 476 staff, including 180 production personnel and 133 R&D personnel[184]. - The educational background of employees includes 8 with PhDs, 20 with master's degrees, and 199 with bachelor's degrees[184]. - The company has established a scientific compensation performance system to enhance employee performance and competitiveness[185]. - The total remuneration for directors and senior management in 2020 amounted to RMB 3.7477 million[181]. - The company has a diverse professional composition, with 76 sales personnel and 48 management personnel[184]. Environmental and Social Responsibility - The company has passed the ISO 14001:2015 environmental management system certification, emphasizing its commitment to sustainable development[148]. - The company has actively supported government food safety projects, enhancing the detection capabilities of food regulatory departments[148]. - The company has not reported any significant environmental pollution during its production processes[148]. - The company plans to continue its focus on health and environmental protection in its operations[148].